Table 2.
Flavonoid | Experimental Model |
Treatment/dose | Mechanism of action or main results | Author/year |
---|---|---|---|---|
Quercetin |
In vivo
Acetic acid induced ulcer gastric in male Wistar rats |
2.5, 5 and 10 mg/kg | (i)Reduction of expression of the pro-inflammatory cytokines TNF-α and IL-6 (ii)Inhibition of COX-2 |
[99] |
In vivo
Isoproterenol-induced myocardial infarction in Wistar rats |
50 mg/kg | (i)Protection against heart damage (ii)Attenuation of oxidative stress (iii)Protection of cardiac architecture (iv)Modulation of calpain expression (v)Reduction of expression of the pro-inflammatory cytokines TNF-α and IL-6 |
[98] | |
In vitro
Human colonic epithelial cell line Caco-2 cell |
200 μM | (i)Inhibition of NLRP3 activation (ii)Reduced ROS production (iii)Reduction in IL-1 and IL-18 levels |
[105] | |
In vivo
Acute necrotizing pancreatitis (ANP) model in rats |
50 mg/kg | (i)Mitigation of damage to the pancreas, ileum, and intestine (ii)Suppression of TLR4/MyD88/p38 and inhibition of endoplasmic reticulum stress |
[103] | |
In vitro
Human middle ear epithelial cells (HMEECs), renal epithelial cells (HK2), and mouse lung epithelial cells (MLE-12), human liver epithelial cells (L02), and human lung epithelial cells (BEAS-2B) |
40, 80 and 120 μM | (i)Suppressed NTHi-induced CXCR4 expression levels in vitro and in vivo (ii)Blocked CXCR4 activation through direct IKKβ phosphorylation inhibition |
[102] | |
In vivo
Otitis NTHi-induced in mice |
20, 40 and 80 mg/kg | |||
| ||||
Isoquercetin |
In vivo
Streptozotocin-induced diabetes in male Wistar rats |
40 mg/kg | (i)Reduction in inflammation marker levels (IL-1β, C-reactive protein, and MPC-1) (ii)Restoration of plasma antioxidant capacity (iii)Inhibition of 12/15-LOX activity in the lungs and liver (iv)Upregulation of HO-1 expression in the joints and lungs (v)Reversal of weight loss, reduction in glucose levels, and increase in insulin production (vi)Increased SOD and CAT activity (vii)Suppression of the inflammatory genes NF-κB, IL-1, IL-6, TLR, TNF-α, and COX-2 |
[109] |
| ||||
Kaempferol |
In vitro
Anti-adipogenic effects on 3 T3-L1 cells |
7.5, 15, and 30 μM | (i) Blockage of 3 T3-L1 differentiation and lipid accumulation in mature adipocytes (ii)Reduction in expression of the adipogenic markers PPARγ and C/EBPα in 3 T3-L1 cells |
[108] |
In vivo
Wild-type zebrafish |
5, 10, and 20 μM | |||
In vitro
Anti-adipogenic effects on 3 T3-L1 cells |
20, 40, 60, 80, 100, 120, 150, and 170 μM | (i)Modulation of adipogenic gene expression in mature adipocytes (ii)Decreased accumulation of lipids in mature adipocytes (iii)Upregulation of Pnpla2 and Lipe mRNA expression |
[110] | |
| ||||
Myricetin | LPS stimulated H9c2 cells | H0, 10, 30, and 50 μM | (i)Reduction in cleaved caspase-3 and Bcl-2 levels (ii)Increase in Bax levels in H9c2 cells (iii)Reduction in MCP-1/CCL-2 and IκBα phosphorylation levels |
[111] |